MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET). A live audio webcast and replay of the discussion may be accessed on the “Investor Calendar” section of the company’s website at: https://event.webcasts.com/starthere.jsp?ei ...

Core Insights - InspireMD, Inc. has appointed Dr. Peter A. Soukas as Chief Medical Officer to enhance its clinical and medical strategy during a critical phase for the company [1][2] Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [5] Leadership Appointment - Dr. Soukas brings extensive experience in vascular intervention, serving as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University, where he founded the Vascular and Endovascular Medicine Fellowship Program [2][3] - His background includes being a principal investigator in over 24 carotid stenting trials and more than 150 endovascular trials, along with delivering over 300 invited lectures and publishing numerous peer-reviewed papers [3] Strategic Vision - Dr. Soukas expressed his commitment to guiding InspireMD in clinical and medical topics, aiming to enhance awareness of the CGuard Prime stent platform and improve patient care through collaboration with clinical partners [4]

Core Insights - InspireMD, Inc. will release its third quarter 2025 financial results on November 4, 2025, and will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss these results and recent highlights [1]. Company Overview - InspireMD, Inc. is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes [1]. - The company utilizes its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, emphasizing outstanding acute results and durable, stroke-free long-term outcomes [2]. Investor Information - Interested parties can access the live earnings call via telephone or through a live webinar on InspireMD's website, with a replay available shortly after the call [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR [2].

Core Viewpoint - InspireMD, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, highlighting its focus on the CGuard® Prime carotid stent system for stroke prevention [1] Company Overview - InspireMD, Inc. aims to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, emphasizing superior acute results and long-term stroke-free outcomes [2] - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2]

Company Overview - InspireMD, Inc. is a developer of the CGuard Prime carotid stent system aimed at preventing strokes [1] - The company utilizes proprietary MicroNet™ mesh technology to enhance the effectiveness of its carotid stenting products [2] Financial Results Announcement - InspireMD will release its second quarter 2025 financial results on August 5, 2025 [1] - A conference call and webcast will be held at 8:30 a.m. Eastern Time to discuss the financial results and recent highlights [1] Access to Earnings Call - Interested parties can access the live earnings call via telephone or through a webcast on InspireMD's website [2] - A replay of the webinar will be available shortly after the call and archived on the company's website [2]